Standardized Extract (HemoHIM) Protects against Scopolamine-Induced Amnesia in a Murine Model

• Published in: Evidence-based complementary and alternative medicine 2021, Vol.2021, p.8884243-11
• Main Authors: Kim, Seul-Ki, Kwon, Da-Ae, Kim, Yong Sang, Lee, Hak Sung, Kim, Hyun Kyu, Kim, Won-Ki
• Format: Article
• Language: English
• Subjects: Acetylcholine receptors (muscarinic); Acetylcholinesterase; Acetyltransferase; Acids; Alzheimer's disease; Amnesia; Animal cognition; Animal models; Brain-derived neurotrophic factor; Choline; Choline O-acetyltransferase; Cyclic AMP response element-binding protein; Dementia; Herbal medicine; Hippocampus; Humidity; Immunological memory; Immunoregulation; Latency; Memory; Mental task performance; Pattern recognition; Polymerase chain reaction; Reverse transcription; Scopolamine; Spontaneous alternation
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2021/8884243

HemoHIM is a medicinal herbal preparation of Angelica gigas Nakai (Apiaceae), Cnidium officinale Makino (Umbelliferae), and Paeonia lactiflora Pallas (Paeoniaceae) designed for immune regulation. In the present study, the memory-enhancing effects of a standardized extract (HemoHIM) on scopolamine-induced memory impairment in a murine model was investigated. To induce amnesia, scopolamine (1 mg/kg) was intraperitoneally (i.p.) injected into mice 30 min before the start of behavioral tests. The Y-maze, novel object recognition test (NORT), and passive avoidance task (PAT) were used to evoke memory functions. HemoHIM significantly improved scopolamine-induced memory impairment in ICR mice, which was evidenced by an improvement of spontaneous alternation in the Y-maze, recognition index in NORT, and latency time in PAT. To elucidate the possible mechanism, the cholinergic activity and mRNA levels of choline acetyltransferase (ChAT), muscarinic acetylcholine receptor (mAchR), brain-derived neurotrophic factor (BDNF), and cAMP response element-binding protein (CREB) were measured using reverse transcription (RT-PCR) and western blot analyses, respectively. HemoHIM treatment attenuated the scopolamine-induced hyperactivation of acetylcholinesterase (AchE) activity. In addition, ChAT, mAchR, and CREB mRNA levels were increased in the hippocampus compared with the scopolamine group. Furthermore, HemoHIM treatment resulted in elevated BDNF protein expression. These results indicate that HemoHIM may exert antiamnesic activity by increasing Ach and inhibiting AchE in the hippocampus. In addition, HemoHIM has therapeutic potential by upregulating ChAT, mAchR, and BDNF, which is apparently mediated by activation of the CREB and ERK signaling pathways.